AveXis Receives U.S. FDA Breakthrough Therapy Designation for AVXS-101 Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
July 20, 2016 07:00 ET
|
AveXis
CHICAGO, July 20, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc., (Nasdaq:AVXS) a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
AveXis Appoints Michael B. Johannesen as Senior Vice President, General Counsel and Chief Compliance Officer
July 11, 2016 08:00 ET
|
AveXis
CHICAGO, July 11, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (Nasdaq:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
AveXis to Present at Goldman Sachs Annual Global Healthcare Conference and Jefferies 2016 Healthcare Conference
June 06, 2016 16:59 ET
|
AveXis, Inc.
CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening...
AveXis Presents Pulmonary Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
May 16, 2016 08:00 ET
|
AveXis, Inc.
CHICAGO, May 16, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing novel treatments for patients suffering from rare and life-threatening...
AveXis Reports First Quarter 2016 Financial and Operating Results
May 12, 2016 16:01 ET
|
AveXis, Inc.
Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 Conference call May 12 at 4:30 p.m. EDT CHICAGO, May 12, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc....
AveXis Reports Data from Ongoing Phase 1 Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
May 06, 2016 15:10 ET
|
AveXis, Inc.
-- Jerry Mendell, MD, Presented Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast Today at 4:30 p.m. Eastern Daylight...
AveXis to Report First Quarter 2016 Financial Results on Thursday, May 12
May 05, 2016 08:00 ET
|
AveXis, Inc.
CHICAGO, May 05, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...
AveXis to Report Data from Ongoing Phase 1 Clinical Trial of AVXS-101 in Spinal Muscular Atrophy Type 1
April 25, 2016 08:00 ET
|
AveXis, Inc.
-- Jerry Mendell, M.D., to Present Data as of April 1, 2016 at the American Society of Gene & Cell Therapy 19th Annual Meeting -- -- Company to Host Webcast on Friday, May 6, 2016 at 4:30 p.m....
AveXis Reports Fourth Quarter and Full Year 2015 Financial and Operating Results
March 16, 2016 16:01 ET
|
AveXis, Inc.
-- Initial public offering raised $98.2 million in net proceeds -- -- Encouraging interim data for lead clinical program, AVXS-101, for Spinal Muscular Atrophy Type 1 – -- Conference call March 16...
AveXis to Report Full Year and Fourth Quarter 2015 Financial Results on Wednesday, March 16
March 08, 2016 08:00 ET
|
AveXis, Inc.
CHICAGO, March 08, 2016 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening...